Print Page     Close Window     

SEC Filings

10-Q
APTEVO THERAPEUTICS INC. filed this Form 10-Q on 11/13/2017
Entire Document
 

 

Alligator shall provide Aptevo with a copy of any such sublicense agreement prior to execution to allow Aptevo to review and confirm compliance with the above; provided that, the terms of any such sublicense agreement may be redacted to the extent not relevant to the determination or enforcement of Aptevo’s rights under this Agreement or the Manufacturing Transition Agreement.  For purposes of clarity, all terms related to the confidentiality and non-use of proprietary information and ownership of intellectual property should not be redacted.

(c)Costs; Aptevo Interim Obligations.  Costs and responsibilities with respect to Process Development and technology transfer of such manufacturing process from Aptevo (or its Existing CMO) to a New CMO shall be allocated in accordance with the following table and not subject to the general cost sharing principles following any Termination Date, as applicable:

Window of Termination Event

Continuing Responsibilities / Cost

[***]

[***]

Pending the validation of, and the production of Product by the Alligator CMO in accordance with all applicable specifications, Aptevo shall continue to Manufacture and supply Product on commercially reasonable terms.

(d)Manufacturing Process Improvements.  For the avoidance of doubt, the technology transfer described in this Section 6.2.2, will cover the manufacturing process for the Product as such manufacturing process and Product exist on the effective date of the Transition Event or, if the Transition Event occurs following the initiation of Process Development but prior to technology transfer of the manufacturing process to a first CMO for GMP manufacturing, as developed by Aptevo pursuant to Section 6.2.2(c), and will not include any rights to any future developments owned or controlled by Aptevo, unless otherwise agreed in

38

[*** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.



© Aptevo BioTherapeutics, LLC.